Classification and Application of the Personalized Glioblastoma Organoids
DOI:
https://doi.org/10.54097/yjs6ea25Keywords:
Personalized glioblastoma organoids; Biobank; Tumor.Abstract
The severe survival rate of glioblastoma especially the recurrent glioblastoma, has directly shown the aggressiveness of glioblastoma and meanwhile, showing the lack of the standardized therapies can be effectively and directly against the glioblatoma in clinical situations. The tumor organoids technology has developed rapidly and the personalized glioblastoma organoids have already been used in several researches about the therapies of glioblastoma as an appropriate model. Comparing with the existed models used in past researches, the tumor organoids show irreplaceable features which will contribute a lot in the researches of glioblastoma including the recapitulation of the microenvironment and the cellular communication of parental tumors. In some researches, personalized tumor organoids were used in drug-screening tests and the final-result show high similarity to the actual situations. The drawbacks of common models greatly hamper the development of novel therapies of glioblastoma because of its inaccuracy in the aspects of the recapitulation and experiment results which will prove a invalid therapy in clinical situations as effective and finally deviate the researches from the correct way. Personalized glioblastoma organoids can be divided into 2 types which is the 3D bioprinting organoids and the patient-derived glioblastoma organoids and each of these maintains own advantages in practical situations. Furthermore, personalized glioblastoma organoids can be stored for much more longer time than the existed organoids which also show the possibilities of applying the glioblastoma organoids into the biobank in order to assist further researches.
Downloads
References
Ratliff M, Kim H, Qi H, Kim M, Ku B, Azorin DD, Hausmann D, Khajuria RK, Patel A, Maier E, Cousin L, Ogier A, Sahm F, Etminan N, Bunse L, Winkler F, El-Khoury V, Platten M, Kwon YJ. Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma. Int J Mol Sci. 2022 Jun 12; 23(12):6572.
Pinto G, Saenz-de-Santa-Maria I, Chastagner P, Perthame E, Delmas C, Toulas C, Moyal-Jonathan-Cohen E, Brou C, Zurzolo C. Patient-derived glioblastoma stem cells transfer mitochondria through tunneling nanotubes in tumor organoids. Biochem J. 2021 Jan 15; 478(1):21-39.
Alshami J., Guiot M., Owen S., Kavan P., Gibson N., Solca F., Cseh A., Reardon D. A., Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. Oncotarget. 2015; 6: 34030-34037.
Clavreul A, Autier L, Lemée JM, Augereau P, Soulard G, Bauchet L, Figarella-Branger D, Menei P, Network F; Collaborators of the FGB network. Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank? Cancers (Basel). 2022 Nov 9; 14(22):5510.
Gómez-Oliva R, Domínguez-García S, Carrascal L, Abalos-Martínez J, Pardillo-Díaz R, Verástegui C, Castro C, Nunez-Abades P, Geribaldi-Doldán N. Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments. Front Oncol. 2021 Jan 29; 10:614295.
Katharina Seystahl, Wolfgang Wick, Michael Weller, Therapeutic options in recurrent glioblastoma—An update, Critical Reviews in Oncology/Hematology, Volume 99,2016, Pages 389-408, ISSN 1040-8428.
Dahan, P., Martinez Gala, J., Delmas, C. et al. ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis 5, e1543 (2014).
Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M, Baharvand H. Personalized Cancer Medicine: An Organoid Approach. Trends Biotechnol. 2018 Apr; 36(4):358-371. doi: 10.1016/j.tibtech.2017.12.005. Epub 2018 Jan 20. PMID: 29366522.
Wen J, Liu F, Cheng Q, Weygant N, Liang X, Fan F, Li C, Zhang L, Liu Z. Applications of organoid technology to brain tumors. CNS Neurosci Ther. 2023 May 29.
Zuhair K. Ballas, the 2018 Nobel Prize in Physiology or Medicine: An exemplar of bench to bedside in immunology, Journal of Allergy and Clinical Immunology, Volume 142, Issue 6, 2018, Pages 1752-1753, ISSN 0091-6749.
Shengchao Xu, Lu Tang, Xizhe Li, Fan Fan, Zhixiong Liu, Immunotherapy for glioma: Current management and future application, Cancer Letters, Volume 476, 2020, Pages 1-12, ISSN 0304-3835.
Hong, X., Chedid, K., & Kalkanis, S.N. (2012). Glioblastoma cell line-derived spheres in serum containing medium versus serum-free medium: A comparison of cancer stem cell properties. International Journal of Oncology, 41, 1693-1700.
Jacob F, Salinas RD, Zhang DY, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020; 180:188-204.e122.
Soubéran A, Tchoghandjian A. Practical Review on Preclinical Human 3D Glioblastoma Models: Advances and Challenges for Clinical Translation. Cancers. 2020; 12(9):2347.
Maria Angeles Marques-Torrejon, Ester Gangoso, Steven M. Pollard; Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture. Dis Model Mech 1 February 2018; 11 (2): dmm031435.
Bayin NS, Ma L, Placantonakis DG, Barcellos-Hoff MH. Evaluation of Radioresponse and Radiosensitizers in Glioblastoma Organotypic Cultures. Methods Mol Biol. 2018; 1741:171-182.
Heinrich, Marcel Alexander, Bansal, Ruchi, Lammers, Twan, Zhang, Yu Shrike, Michel Schiffelers, Raymond, Prakash, Jai,1806590,3D-Bioprinted Mini-Brain: A Glioblastoma Model to Study Cellular Interactions and Therapeutics, Advanced Materials, Adv. Mater.31,14, SN 0935-9648, SP - 1806590
Christopher G. Hubert, Maricruz Rivera, Lisa C. Spangler, Qiulian Wu, Stephen C. Mack, Briana C. Prager, Marta Couce, Roger E. McLendon, Andrew E. Sloan, and Jeremy N. Rich; A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res 15 April 2016; 76 (8): 2465–2477.
Miguel A. Hermida, Jothi Dinesh Kumar, Daniela Schwarz, Keith G. Laverty, Alberto Di Bartolo, Marcus Ardron, Mihails Bogomolnijs, Anne Clavreul, Paul M. Brennan, Ulrich K. Wiegand, Ferry PW. Melchels, Will Shu, Nicholas R. Leslie, Three dimensional in vitro models of cancer: Bioprinting multilineage glioblastoma models, Advances in Biological Regulation, Volume75, 2020,100658, ISSN 2212-4926.
Maloney E, Clark C, Sivakumar H, Yoo K, Aleman J, Rajan SAP, Forsythe S, Mazzocchi A, Laxton AW, Tatter SB, et al. Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput. Micromachines. 2020; 11(2):208.
Casey C. Clark, Julio Aleman, Lysette Mutkus, Aleksander Skardal, A mechanically robust thixotropic collagen and hyaluronic acid bioink supplemented with gelatin nanoparticles, Bioprinting, Volume16, 2019, e00058, ISSN2405-8866.
Shakya, S., Gromovsky, A.D., Hale, J.S. et al. Altered lipid metabolism marks glioblastoma stem and non-stem cells in separate tumor niches. acta neuropathol commun 9, 101 (2021).
Jacob F, Ming GL, Song H. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. Nat Protoc. 2020 Dec; 15(12):4000-4033.Epub 2020 Nov 9. PMID: 33169003.
Golebiewska, A., Hau, AC., Oudin, A. et al. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology. Acta Neuropathol 140, 919–949 (2020).
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







